ProfileGDS5678 / 1427423_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 68% 68% 67% 67% 69% 68% 68% 68% 68% 68% 67% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1649968
GSM967853U87-EV human glioblastoma xenograft - Control 24.130368
GSM967854U87-EV human glioblastoma xenograft - Control 34.134568
GSM967855U87-EV human glioblastoma xenograft - Control 44.0674667
GSM967856U87-EV human glioblastoma xenograft - Control 54.0782467
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2728869
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2206368
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1349968
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1359368
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1677968
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1368968
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1065867
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1496368
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1411968